Saturday 17 October 2026
Export ALNY’s income statement to Excel — free account
Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.
231.83
2.20
−0.94%
Follow ALNY
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | 2 | 2 | 4 | 3 | 3 | 5 | 5 | 6 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 163.12 |
P/S ratio |
70.13 | 132.79 | 97.91 | 57.26 | 30.32 | 23.79 | 27.40 | 13.32 | 13.36 | 14.03 |
Altman Z-Score |
3.22 | 28.92 | 12.72 | 5.20 | 1.92 | 2.14 | 2.30 | 1.84 | 2.90 | 7.30 |
Altman Z″-Score (non-manufacturers) |
(0.91) | 8.26 | (0.09) | (2.40) | (1.67) | (2.17) | (4.01) | (3.07) | (2.60) | (0.11) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 580.47 | 0.00 | 111.94 |
P/Operating CF |
(42.22) | (115.87) | (48.74) | (64.21) | (121.36) | (133.79) | (215.38) | (817.18) | (317.31) | 318.51 |
Beneish M-Score |
(2.03) | (2.25) | (3.71) | (1.52) | 3.21 | (3.03) | (3.07) | (2.66) | (2.50) | (1.95) |
P/B ratio |
3.59 | 6.76 | 5.63 | 8.75 | 14.71 | 34.15 | 0.00 | 0.00 | 447.73 | 66.01 |
Price to Tangible BV |
3.59 | 6.76 | 5.63 | 8.75 | 14.71 | 34.15 | 0.00 | 0.00 | 447.73 | 66.01 |
EV/Sales |
60.02 | 114.32 | 83.83 | 51.53 | 26.91 | 21.71 | 26.27 | 12.54 | 12.62 | 13.51 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 90.08 |
EV/Operating CF |
(9.20) | (26.85) | (11.16) | (40.67) | (21.56) | (28.56) | (50.34) | 220.14 | (3,412.86) | 95.77 |
EV/FCF |
(7.60) | (21.11) | (9.11) | (27.05) | (19.35) | (25.52) | (44.43) | 546.65 | (666.08) | 107.85 |
Quick Ratio |
4.94 | 11.96 | 6.14 | 4.48 | 4.23 | 3.79 | 3.16 | 2.86 | 2.61 | 2.51 |
Current Ratio |
5.10 | 12.23 | 6.69 | 4.87 | 4.47 | 4.04 | 3.51 | 3.08 | 2.78 | 2.76 |
Net Debt/EBITDA |
1.16 | 3.40 | 1.32 | 1.42 | 2.23 | 2.84 | 1.59 | 6.22 | 13.89 | (3.41) |
Debt/Assets |
11.88% | 1.50% | 1.91% | 11.52% | 5.61% | 18.55% | 28.68% | 26.65% | 24.17% | 20.29% |
Debt/Equity |
0.16 | 0.02 | 0.02 | 0.19 | 0.19 | 1.15 | (6.43) | (4.63) | 15.27 | 1.28 |
Asset Turnover |
0.04 | 0.06 | 0.04 | 0.11 | 0.17 | 0.24 | 0.29 | 0.50 | 0.56 | 0.81 |
Operating CF/Net income |
0.75 | 0.78 | 0.74 | 0.31 | 0.72 | 0.75 | 0.48 | (0.24) | 0.03 | 1.67 |
Capex/Depreciation |
(4.27) | (8.76) | (8.32) | (2.58) | (0.95) | (0.85) | (1.62) | (1.15) | (0.60) | (1.05) |
Interest Coverage |
(51.11) | (40.87) | (28.09) | (28.47) | (9.80) | (4.95) | (5.03) | (2.33) | (1.25) | 1.99 |
| (37.54%) | (36.54%) | (49.63%) | (64.66%) | (69.92%) | (106.31%) | (526.14%) | 232.40% | 362.29% | 73.28% | |
| (30.96%) | (30.14%) | (42.67%) | (44.64%) | (29.58%) | (24.19%) | (31.47%) | (11.94%) | (6.89%) | 6.82% | |
ROIC |
(59.85%) | (295.38%) | (205.47%) | (328.88%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(62.64%) | (27.23%) | (56.75%) | (49.55%) | (34.41%) | (32.61%) | (46.21%) | (17.33%) | (10.65%) | 10.13% |
Average Days of Receivables |
180.60 | 138.03 | 91.41 | 71.44 | 446.14 | 85.85 | 83.72 | 65.44 | 65.80 | 76.42 |
Research and Development Expense of Revenue |
810.86% | 434.46% | 674.72% | 298.12% | 132.86% | 93.83% | 85.12% | 54.94% | 50.09% | 35.54% |
Selling, General and Administrative Expense of Revenue |
189.47% | 221.73% | 510.44% | 217.98% | 119.39% | 73.51% | 74.29% | 43.52% | 43.39% | 32.60% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
160.16% | 103.23% | 210.59% | 79.56% | 28.38% | 19.63% | 22.23% | 12.12% | 12.10% | 9.38% |
Graham Net Nets |
0.10 | 0.13 | 0.13 | 0.06 | 0.02 | (0.01) | (0.04) | (0.04) | (0.03) | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.49 | 11.84 | 0.00 | 18.18 |
Earnings Yield |
(12.40%) | (4.10%) | (10.37%) | (7.07%) | (5.73%) | (4.25%) | (3.98%) | (1.81%) | (0.92%) | 0.61% |
Free Cash Flow Yield |
(11.26%) | (4.08%) | (9.40%) | (3.33%) | (4.59%) | (3.57%) | (2.16%) | 0.17% | (0.14%) | 0.89% |
Revenue per Share |
0.55 | 0.99 | 0.74 | 2.01 | 4.29 | 7.13 | 8.53 | 14.64 | 17.61 | 28.35 |
Operating CF per Share |
(3.59) | (4.23) | (5.59) | (2.55) | (5.35) | (5.42) | (4.45) | 0.83 | (0.07) | 4.00 |
Capex per Share |
(0.75) | (1.15) | (1.26) | (1.28) | (0.61) | (0.64) | (0.59) | (0.50) | (0.27) | (0.45) |
Free Cash Flow per Share |
(4.35) | (5.38) | (6.85) | (3.83) | (5.96) | (6.06) | (5.04) | 0.34 | (0.33) | 3.55 |
Cash per Share |
7.32 | 18.67 | 10.78 | 14.06 | 16.30 | 20.56 | 18.02 | 19.53 | 21.11 | 22.20 |
Shareholders Equity per Share |
10.75 | 19.51 | 12.94 | 13.17 | 8.84 | 4.97 | (1.30) | (1.77) | 0.53 | 6.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.75 | 19.51 | 12.94 | 13.17 | 8.84 | 4.97 | (1.30) | (1.77) | 0.53 | 6.02 |
Free Cash Flow |
(372.26) | (486.99) | (689.50) | (418.58) | (685.32) | (718.06) | (613.33) | 41.95 | (42.59) | 465.38 |
Working Capital |
540.18 | 1,620.49 | 1,021.20 | 1,363.27 | 2,029.51 | 2,112.87 | 1,924.33 | 2,014.91 | 2,109.01 | 2,584.31 |
Capital Expenditures |
(64.56) | (104.21) | (126.89) | (140.16) | (70.36) | (76.37) | (72.06) | (62.21) | (34.28) | (58.70) |
Net Current Asset Value |
329.29 | 1,536.44 | 927.86 | 759.42 | 223.96 | (246.52) | (1,012.33) | (1,067.83) | (877.61) | (126.49) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.07 |
Capex to Sales |
1.37 | 1.16 | 1.69 | 0.64 | 0.14 | 0.09 | 0.07 | 0.03 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.86 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.07 | 0.05 | 0.13 | 0.16 | 0.18 | 0.08 | 0.10 | 0.11 | 0.11 |
Cash ROIC |
(21.94%) | (13.97%) | (28.54%) | (12.88%) | (22.24%) | (19.41%) | (20.10%) | 1.29% | (1.12%) | 9.89% |
Accounts Receivable Turnover |
2.98 | 3.14 | 2.84 | 7.12 | 1.53 | 2.11 | 4.75 | 6.46 | 6.13 | 6.28 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.04 | 0.46 | 1.53 | 2.24 | 1.97 | 4.04 | 4.49 | 6.68 |
Inventory Turnover |
— | — | 0.05 | 0.62 | 1.19 | 1.73 | 1.57 | 2.85 | 3.86 | 8.46 |
Average Days of Payables |
0.00 | 0.00 | 12,094.02 | 726.50 | 243.01 | 191.24 | 212.09 | 65.28 | 99.80 | 61.94 |
Days of Inventory on Hand |
— | — | 4,875.04 | 820.65 | 351.67 | 224.93 | 278.83 | 104.82 | 88.62 | 44.28 |
Average Receivables |
15.82 | 28.67 | 26.38 | 30.89 | 322.71 | 400.49 | 218.27 | 282.88 | 366.55 | 591.44 |
Average Payables |
35.63 | 41.41 | 44.03 | 54.80 | 50.93 | 62.70 | 85.76 | 76.81 | 71.97 | 102.07 |
Average Inventory |
— | — | 40.00 | 40.21 | 65.78 | 80.78 | 107.66 | 109.05 | 83.83 | 80.61 |
Average Assets |
1,324.66 | 1,628.77 | 1,784.77 | 1,984.97 | 2,901.10 | 3,525.18 | 3,594.83 | 3,688.12 | 4,034.93 | 4,603.16 |
Average Common Equity |
1,092.47 | 1,343.33 | 1,534.20 | 1,370.33 | 1,227.47 | 802.23 | 214.99 | (189.43) | (76.78) | 428.13 |
Columns are period end dates